<PAGE> 1
<TABLE>
<S> <C>
---------------------------
OMB APPROVAL
---------------------------
UNITED STATES OMB Number: 3235-0145
SECURITIES AND EXCHANGE COMMISSION Expires: October 31, 1994
Washington, D.C. 20549 Estimated average burden
hours per response... 14.90
---------------------------
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. ______________)*
</TABLE>
GENOVESE DRUG STORES, INC.
(Name of Issuer)
CLASS A COMMON STOCK, PAR VALUE $1.00 PER SHARE
(Title of Class of Securities)
372442202
(CUSIP Number)
Check the following box if a fee is being paid with this statement / /. (A fee
is not required only if the filing person: (1) has a previous statement on
file reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7).
- -------------------------------
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).
Page 1 of 5 pages
<PAGE> 2
CUSIP No. 372442202 13G Page 2 of 5 Pages
________________________________________________________________________________
1 NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
Frances Genovese Wangberg
________________________________________________________________________________
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) / /
(b) / /
________________________________________________________________________________
3 SEC USE ONLY
________________________________________________________________________________
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States of America
________________________________________________________________________________
NUMBER OF 5 SOLE VOTING POWER
SHARES 1,710,003
________________________________________________________
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 0
________________________________________________________
EACH 7 SOLE DISPOSITIVE POWER
REPORTING 1,710,003
________________________________________________________
PERSON WITH 8 SHARED DISPOSITIVE POWER
0
________________________________________________________________________________
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,710,003
________________________________________________________________________________
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
/ /
________________________________________________________________________________
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
25.8%
________________________________________________________________________________
12 TYPE OF REPORTING PERSON*
IN
________________________________________________________________________________
*SEE INSTRUCTIONS BEFORE FILLING OUT!
Page 2 of 5 pages
<PAGE> 3
ITEM 1(a). NAME OF ISSUER:
Genovese Drug Stores, Inc.
ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
80 Marcus Drive
Melville, NY 11747
ITEM 2(a). NAME OF PERSON FILING:
Frances Genovese Wangberg
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
80 Marcus Drive
Melville, NY 11747
ITEM 2(c). CITIZENSHIP:
United States of America
ITEM 2(d). TITLE OF CLASS OF SECURITIES:
Class A Common Stock, par value $1.00 per share
ITEM 2(e). CUSIP NUMBER:
372442202
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b), OR 13d-2(b),
CHECK WHETHER THE PERSON FILING IS A:
Not applicable
ITEM 4. OWNERSHIP.
(a) AMOUNT BENEFICIALLY OWNED:
1,710,003
(b) PERCENT OF CLASS:
25.8%
(c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:
(i) SOLE POWER TO VOTE OR TO DIRECT THE VOTE
1,710,003
(ii) SHARED POWER TO VOTE OR TO DIRECT THE VOTE
0
(iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF
1,710,003
Page 3 of 5 pages
<PAGE> 4
(iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF
0
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
Not applicable
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
Not applicable
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
Not applicable
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
Not applicable
ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
Not applicable
ITEM 10. CERTIFICATION.
Not applicable
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is
true, complete and correct.
February 7, 1995
----------------------------------------
(Date)
/s/ Frances Genovese Wangberg
----------------------------------------
(Signature)
Frances Genovese Wangberg
----------------------------------------
(Name/Title)
Page 4 of 5 pages
<PAGE> 5
ANNEX A TO SCHEDULE 13G OF FRANCES GENOVESE WANGBERG
The aggregate number of shares shown as beneficially owned by the Reporting
Person includes the effect of a 10% stock dividend paid in January 1995.
Of the aggregate number of shares shown as beneficially owned by the Reporting
Person, 1,695,562 are beneficially owned in the form of the Issuer's Class B
Common Stock, par value $1.00 per share, which class is not registered as a
class of equity securities under the Securities Act of 1933, and 11,784 are
owned in the form of options exercisable for shares of the Issuer's Class A
Common Stock, all of which can be converted within 60 days into an equal
number of shares of the Issuer's Class A Common Stock. Of such number of
shares of the Issuer's Class B Common Stock, 1,431,686 are beneficially owned
as Trustee under the Trust under the Will of the late Joseph W. Genovese, Jr.
and the Reporting Person is the sole beneficiary of such trust.
Page 5 of 5 pages
